The two most advanced PCa immunotherapies, the licensed product Sipuleucel-T [2] and ProstVac [3] currently being tested in Phase III trial, target two well-defined PCa antigens, prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA), respectively. Here, KLK3 is linked to posterior cortical atrophy.